MBX Biosciences, Inc.
MBX· Nasdaq
Released Aug 7, 2025, before the open
10-Q filed Aug 7, 2025, 38 days after period end · 0000950170-25-104619
| Metric | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|
| Net Income | -$19.41M | -$15.86M | -$7.61M |
| EPS Diluted | -$0.58 | -$12.62 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MBX Biosciences, Inc. · CIK 1776111 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end
4.7% from the close of Aug 6, 2025 to the close of Aug 7, 2025, the first after the release.